On this page
Hypochondroplasia
This condition is a form of skeletal dysplasia, characterised by shorter limbs in proportion to the trunk, along with other skeletal features. It typically becomes apparent in early childhood.
Available at Jeen Health
Clinical tests that include this
Overview
Hypochondroplasia is a genetic condition that affects how bones grow, resulting in a type of short stature where the limbs are shorter than usual in comparison to the body's trunk. It is considered a milder form of skeletal dysplasia, a group of conditions that cause abnormal development of cartilage and bone. While individuals with hypochondroplasia are shorter than average, their overall health and intellectual development are typically unaffected [PMID:32014131].
The features of hypochondroplasia often become noticeable during early childhood. The condition affects individuals worldwide, though its exact prevalence can vary. Research suggests that approximately 1 in 15,000 to 40,000 people may be affected by hypochondroplasia [PMID:32014131].
Symptoms & clinical features
Individuals with hypochondroplasia generally present with disproportionate short stature. This means their arms and legs are shorter than expected relative to their trunk length. The hands and feet may also appear shorter and broader. Other skeletal features can include a relatively large head, and sometimes a slightly prominent forehead.
While spinal issues are less common than in some other skeletal dysplasias, some individuals may develop a curved spine (scoliosis) or a narrowing of the spinal canal (spinal stenosis) in the lower back, which can potentially cause nerve compression. Joint laxity (looseness) or limitation of movement in certain joints has also been observed in some cases [PMID:17963385]. Importantly, general health and cognitive abilities are typically not impacted by hypochondroplasia.
Video: Genetics 101
Affected organs
Hypochondroplasia primarily affects the skeletal system, particularly the long bones of the limbs and, to a lesser extent, the spine. The abnormal bone growth primarily affects the cartilage growth plates at the ends of bones, which are crucial for increasing bone length during childhood and adolescence. While other organs are not directly affected by the condition itself, potential skeletal complications like spinal stenosis could indirectly impact neurological function if nerves become compressed.
Risks & severity
The severity of hypochondroplasia can vary between individuals, even within the same family. It is generally considered a milder skeletal dysplasia compared to other conditions affecting the same gene, such as achondroplasia. While many individuals experience only mild short stature, some may have more pronounced skeletal features or develop complications like spinal stenosis, which might require medical attention.
The condition is present from birth, though features may not be immediately obvious and often become more apparent as a child grows. There are typically no known increased risks for other severe health problems or reduced life expectancy associated with hypochondroplasia.
Genetic causes
Hypochondroplasia is caused by genetic changes (variants) in the FGFR3 gene. This gene provides instructions for making a protein called fibroblast growth factor receptor 3. This protein plays a critical role in regulating bone growth by controlling the rate at which cartilage cells at the ends of bones (growth plates) multiply and turn into bone.
Pathogenic variants in the FGFR3 gene lead to an overactive FGFR3 protein. This overactivity results in the premature closure of the growth plates, meaning the long bones stop growing in length too soon. This mechanism explains the disproportionate short stature observed in individuals with hypochondroplasia [PMID:10729227].
- FGFR3 fibroblast growth factor receptor 3The FGFR3 gene provides instructions for making fibroblast growth factor receptor 3, a protein crucial for regulating cell growth, differentiation, and especially skeletal development.
Inheritance pattern
Hypochondroplasia is inherited in an autosomal dominant pattern. This means that a person only needs to inherit one copy of the altered FGFR3 gene from either parent to develop the condition. If a parent has hypochondroplasia, there is a 50% chance with each pregnancy that their child will also inherit the condition.
In some cases, hypochondroplasia can result from a new, spontaneous genetic change in the FGFR3 gene, meaning neither parent carries the altered gene. This is known as a de novo variant. In such instances, the chance of future children in that family having the condition is very low, but the affected individual would have a 50% chance of passing it on to their own children.
Each child has a 50% chance of inheriting the pathogenic variant, regardless of sex.
Diagnosis & testing
Diagnosis of hypochondroplasia typically begins with a clinical examination where a doctor observes characteristic physical features, such as disproportionate short stature and limb shortening. X-rays can help confirm skeletal abnormalities consistent with the condition. These might include changes in the long bones and spine.
Confirmation of hypochondroplasia is achieved through genetic testing, which looks for pathogenic variants in the FGFR3 gene. A referral to a clinical genetics service can be made by a GP or specialist paediatrician to discuss genetic testing options. Genetic testing for skeletal dysplasias, including hypochondroplasia, falls under the NHS Genomic Medicine Service (GMS) pathways, often within R-codes such as R18 (Skeletal dysplasia) or R26 (Short stature, genetic). Genetic counsellors can provide further information and support regarding testing and its implications.
Management & lifestyle
Management of hypochondroplasia in the UK is primarily supportive and aims to address any symptoms or complications that may arise. Regular monitoring by paediatricians and, if necessary, orthopaedic specialists is common. This monitoring might involve tracking growth, assessing spinal curvature, and checking for any signs of spinal canal narrowing (spinal stenosis).
If spinal stenosis develops and causes symptoms, surgical intervention may be considered to relieve pressure on the spinal cord or nerves. Physical therapy may be recommended to help maintain joint mobility and muscle strength. Genetic counselling is an important part of the management pathway, providing information about the condition, inheritance patterns, and support for families. Growth hormone therapy is generally not effective for hypochondroplasia, as the underlying issue is with growth plate regulation rather than growth hormone deficiency.
UK care pathway
In the UK, individuals suspected of having a genetic condition like hypochondroplasia can access care through the NHS Genomic Medicine Service. This typically begins with a referral from a GP or specialist to a clinical genetics service. Clinical geneticists and genetic counsellors are key professionals who can provide a diagnosis, explain the genetic basis of the condition, and discuss inheritance patterns and management strategies. Genetic testing for skeletal dysplasias is available through the NHS GMS, often referenced by specific R-codes such as R18 (Skeletal dysplasia) or R26 (Short stature, genetic). Genetic counsellors play a vital role in supporting individuals and families through the diagnostic process and beyond.
Frequently asked questions
What is the life expectancy for someone with hypochondroplasia?
Individuals with hypochondroplasia typically have a normal life expectancy. The condition primarily affects bone growth and does not generally impact overall health or lifespan.
Will my child's intelligence be affected by hypochondroplasia?
No, hypochondroplasia does not typically affect intellectual development. Children with this condition generally have cognitive abilities within the normal range.
Is there a cure for hypochondroplasia?
Currently, there is no cure for hypochondroplasia. Management focuses on addressing symptoms and potential complications, such as spinal issues, to support an individual's health and well-being.
How is hypochondroplasia different from achondroplasia?
Both hypochondroplasia and achondroplasia are caused by variants in the FGFR3 gene, but achondroplasia is generally a more severe condition. Individuals with achondroplasia typically have more pronounced short stature and distinct facial features, while hypochondroplasia is considered a milder form of skeletal dysplasia.
Can growth hormone treatment help with hypochondroplasia?
Growth hormone therapy is generally not effective for hypochondroplasia. The short stature in this condition is due to an issue with how growth plates function, rather than a deficiency in growth hormone itself.
References
- Ornitz DM, Legeai-Mallet L. Achondroplasia: Development, pathogenesis, and therapy. Developmental dynamics : an official publication of the American Association of Anatomists. 2017. PMID: 27987249
- Adam MP, Bick S, Mirzaa GM. Hypochondroplasia. 1993. PMID: 20301650
- Cheung MS, Cole TJ, Arundel P. Growth reference charts for children with hypochondroplasia. American journal of medical genetics. Part A. 2024. PMID: 37814549
- Specht EE, Daentl DL. Hypochondroplasia. Clinical orthopaedics and related research. 1975. PMID: 1098822
- Dauber A, Zhang A, Kanakatti Shankar R. Vosoritide treatment for children with hypochondroplasia: a phase 2 trial. EClinicalMedicine. 2024. PMID: 38813446
- Xue Y, Sun A, Mekikian PB. FGFR3 mutation frequency in 324 cases from the International Skeletal Dysplasia Registry. Molecular genetics & genomic medicine. 2014. PMID: 25614871
- Kang C. Navepegritide: First Approval. Drugs. 2026. PMID: 42234372
- Newman DE, Dunbar JC. Hypochondroplasia. Journal of the Canadian Association of Radiologists. 1975. PMID: 1158967